734 results about "Leukemia" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof, and relates to the field of genetic engineering, in particular to a hybridoma cell strain, a monoclonal antibody, a linear epitope antigen and application thereof. The preservation number of the hybridoma cell strain P27-A1 is CGMCC (China General Microbiological Culture Collection Center) No. 46352. The hybridoma cell strain P27-A1 is prepared from feline leukemia virus p27, and a monoclonal antibody secreted by the hybridoma cell strain P27-A1 recognizes a linear epitope antigen of feline leukemia virus p27 protein; the kit for the feline leukemia virus p27 comprises the monoclonal antibody A1 secreted by the hybridoma cell strain P27-A1. The monoclonal antibody secreted by the hybridoma cell strain can greatly improve the sensitivity of the p27 protein for detecting feline leukemia virus. The invention provides the monoclonal antibody secreted by the hybridoma cell strain for identification, and the monoclonal antibody can be used for preparing a diagnostic kit such as a colloidal gold test strip.

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

The invention belongs to the technical field of immunoassay and biosensing, and provides a novel construction mode of a heterojunction dual-photoelectrode photoelectric sensing strategy and a preparation method of an in-situ heterojunction MIO photocathode. The invention relates to a preparation method of a heterojunction dual-photoelectrode type photoelectrochemical sensor based on multi-ball cascade DNA reaction amplification. Specifically, the design is composed of an In2O3 / CdS photoanode and an in-situ formed MIL-68 / In2O3 (MIO) photocathode. The heterojunction dual-photoelectrode sensing strategy effectively prolongs an electron-hole transmission path, enhances photo-generated charge separation, and realizes' super-open 'PEC signal output, thereby providing a steady baseline for signal conversion. Meanwhile, a multi-sphere cascade DNA reaction is combined to output a three-dimensional DNA net structure to provide a large number of sites for embedding of a PEC quenching probe doxorubicin-ferrocene carboxylic acid (DOX-FcCOOH), obvious PEC signal quenching is realized by utilizing the efficient competitive electron transfer capability of the three-dimensional DNA net structure, and finally, a signal conversion system with'opening-super opening-closing 'multistage response characteristics is constructed. The detection of the nucleic acid marker Pax-5a gene of the B cell acute lymphatic leukemia is realized by detecting target objects with different concentrations.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The invention relates to the technical field of natural compounds, in particular to ganoderma leukemia polysaccharide and a preparation method thereof. The ganoderma leukemia polysaccharide comprises galactose, glucose and mannose, and the molar ratio of the galactose to the mannose to the glucose is (1.5-3.5): (15-30): (65-85); the ganoderma leukemia polysaccharide comprises:-> 6)-Glcp-(1-> dominant residues; (-> 6)-Manp-(1->,-> 4)-Glcp-(1-> residue; and-> 4, 6)-Manp-(1->,-> 3, 6)-Galp-(1->. The ganoderma leukemia polysaccharide has anti-oxidation and detoxification capabilities, can avoid neurodegenerative diseases, reduce lipid accumulation and prolong the service life, and also has high-temperature resistance.

The invention relates to the technical field of electrocardiosignal detection, in particular to a leukemia child cardiotoxicity prediction system based on electrocardio dynamic evolution characteristics, which comprises the following steps: acquiring electrocardiosignals of a leukemia child in a whole chemotherapy cycle; performing empirical mode decomposition on the preprocessed electrocardiosignal, and performing dynamic modeling on an empirical mode decomposition result to obtain time domain representation and dynamic domain representation under different scales; performing cross-domain fusion on the time domain representation and the dynamic domain representation under different scales to obtain multi-scale dynamic and static characteristics; on the basis of the multi-scale dynamic and static characteristics, electrocardio time-varying dynamic evolution characteristics of the child patient in the whole chemotherapy period are calculated; based on the electrocardio time-varying dynamic evolution characteristics of the whole chemotherapy cycle of the child patient, predicting an early prediction result of cardiotoxicity of the child patient; and explaining the prediction result to obtain the causal relationship between the cardiotoxicity and the electrocardio time-varying dynamic evolution characteristics. And the accuracy of cardiac toxicity prediction is improved.

The invention discloses a limonin compound and application thereof in preparation of a medicine for preventing and / or treating cancers. The structure of the limonin compound is shown as a formula I or II. The cancer is at least one of breast cancer, liver cancer, gastric cancer, esophageal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, prostatic cancer, nasopharynx cancer, cervical cancer, ovarian cancer, kidney cancer and skin cancer. According to the invention, activity screening is carried out on various natural product extracts, it is found for the first time that limonin compounds with structural formulas I and II have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. Related results also show that the compound provided by the invention can inhibit migration and invasion ability of breast cancer cells, promote cell apoptosis and retard a cell cycle. The limonin compound applied in the invention is derived from mallotus oblongifolius, the source is wide, and the production cost is low.

The invention discloses an application of EIF5B in treatment of leukemia. According to the application, the translation initiation factor EIF5B which is generally highly expressed in various subtype AML patients is found for the first time, specifically participates in maintaining the function of an AML cell line, does not influence the function of normal HSPC, and is expected to become a broad-spectrum AML treatment target.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention discloses an antibody combination and a system for detecting leukemia stem cells. The antibody combination comprises a CD7 antibody, a CD371 antibody, a CD34 antibody, a CD45RA antibody, a CD123 antibody, a CD133 antibody, a CD38 antibody, a CD45 antibody, a CD90 antibody, a CD33 antibody and a CD19 antibody. The antibody combination provided by the invention can accurately identify target cells and distinguish normal HSCs and pluripotent progenitor cells in a CD34 + CD38-cell population, and the specific antibody has abnormal expression or expression intensity change, so that leukemia stem cells can be rapidly, simply and conveniently detected with high accuracy, high sensitivity and high specificity, the sensitivity of MRD evaluation is favorably improved, and the kit has a good application prospect. Therefore, signs of disease recurrence can be found earlier, more information about disease prognosis can be provided, and doctors and patients can be helped to better understand disease prognosis and possible results.

Compositions and methods are provided for reducing NPM1 glutamate-glutamylation and for treating cancers characterized by overexpression of TTLL4 and / or expression of a mutant NPM1.

The present invention relates to an antigenic peptide targeting FLT3-D835 mutation and its application in tumor immunotherapy. Specifically, the present invention provides an antigenic peptide for eliciting an immune response targeting FLT3-D835 mutation. Compared with the lack of affinity between the wild-type polypeptide and HLA-A * 02:01 molecule, the antigenic peptide of the present invention has high affinity for HLA-A * 02:01 molecule. The present invention also provides the application of the antigenic peptide of the present invention. The antigenic peptide of the present invention has good immunogenicity, can activate specific immune responses, and has important clinical significance for targeting the clearance of leukemia cells, stabilizing the remission state of AML patients, and prolonging the disease-free survival time.

Provided herein are compounds that promote targeted degradation of IKZF1, IKZF2, GSPT1, and / or CK1a, proteins whose activities are implicated in the pathology of certain cancers (e.g., acute myeloid leukemia). Also provided are pharmaceutical compositions comprising the compounds. Also provided are methods of treating cancer, and methods of promoting the degradation of IKZF1, IKZF2, GSPT1, and / or CK1a in a subject or biological sample by administering a compound or composition described herein.

The invention belongs to the field of intelligent equipment, and particularly relates to a system for automatically distinguishing leukemia types based on flow cytometry. The invention aims to solve the problem of low leukemia identification accuracy in the prior art. The invention provides a system for automatically distinguishing leukemia types based on flow cytometry. The system comprises a data acquisition module, a feature analysis module and a prediction and diagnosis module, the data acquisition module is used for processing bone marrow puncture fluid of a to-be-detected person to obtain a cell event data set of the to-be-detected person; the feature analysis module is used for processing a cell event data set of a to-be-detected person to obtain extraction features; the prediction and diagnosis module is used for processing extracted feature prediction to obtain a diagnosis conclusion; according to the system, through a standardized data preprocessing process, the analysis duration can be compressed to be within 20 minutes, the diagnosis consistency is improved to 98% or above, and the detection sensitivity reaches the 0.001% level.

The present invention includes compositions and methods for retrieving tumor-related antibodies and antigens. In one aspect, the invention includes a method for Sequential Tumor-related Antibody and antigen Retrieving (STAR) which directly and efficiently identifies potent antibodies that can specifically bind to tumor-related antigens on the tumor cell surface. In another aspect, the invention includes a CAR comprising a nanobody, a transmembrane domain, and an intracellular domain, wherein the nanobody is retrieved by a STAR method. In another aspect, the invention includes a CAR T system that targets CD13 and treats acute myeloid leukemia. In another aspect, the invention includes a CAR T system and ADC that targets CDH17 and treats NETs and other types of tumors expressing this antigen, with tolerable toxicities.

This application relates to the technical field of pharmaceutical preparations, and specifically discloses a pharmaceutical composition containing ibrutinib and its preparation method. The composition includes the active ingredient ibrutinib, colloidal silicon dioxide, solubilizers, and other excipients such as excipients; its preparation method is: the active ingredient ibrutinib is preferentially mixed with colloidal silicon dioxide and solubilizers, followed by dry granulation, mixing, and capsule filling. The composition of this application can be used for the treatment of diseases such as mantle cell lymphoma (MCL) / chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma, etc. It can effectively break the insoluble complex salt formed by ibrutinib and solubilizers, and has the advantages of fast dissolution rate and significantly improved bioavailability; in addition, the preparation method of this application has the advantages of good process reproducibility, simple process steps, low production cost, and being suitable for large-scale industrial production.

The invention discloses a benzimidazole compound as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. The benzimidazole compound provided by the invention has a good inhibition effect on kinase RET, VEGFR2 and epigenetic protein HDAC1, can be used as a novel kinase / HDAC multifunctional inhibitor, is used for preventing and / or treating various diseases related to RET, VEGFR2 and HDAC, such as leukemia, has an excellent effect, and has a good application prospect.

The invention discloses preparation and application of grouper enterospora sporowall protein SWP26 and a polyclonal antibody of the grouper enterospora sporowall protein SWP26, and belongs to the field of animal quarantine, the grouper enterospora sporowall protein SWP26 is obtained by amplifying grouper enterospora genes by using a PCR (Polymerase Chain Reaction) method, shearing a target band and transferring the target band into a pET-32a vector to construct a recombinant plasmid, and then transforming escherichia coli BL21 (DE3) for induced expression. A Ni-NTA affinity chromatography method is used for protein purification, animal immunization and polyclonal antibody purification are carried out on the purified SWP26 recombinant protein, western blot detection is carried out on the purified antibody, an obvious signal appears at about 43kDa, and it is proved that the anti-SWP26 polyclonal antibody can be subjected to a specific reaction with the SWP26 purified protein. The invention clones and identifies the high-abundance spore wall protein SWP26 positioned on the surface of the enterosporidium of the grouper for the first time, belongs to a specific protein of the enterosporidium of the grouper, and can be used as a drug target for treating enterocytozoonosis of the grouper.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and / or CD20 positive cells and can be used to treat CD19 and / or CD20 positive B-cell lymphoma, leukemia and other diseases.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The present invention provides therapies for the treatment of CCR9 positive cancers, such as T cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The invention also relates to a CCR9 targeting moiety comprising another targeting moiety, preferably a CD1a targeting moiety, to a dual CAR comprising CCR9 and CD1a targeting moieties, to the use thereof in the treatment of CCR9 and / or CD1a positive cancers, and to the use of a CCR9 targeting moiety and a CD1a targeting moiety alone for such treatments.

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.

The invention relates to a management method and system for a leukemia cell morphology intelligent recognition microscopic device, and solves the problems that imaging quality fluctuates, suspicious cell recognition precision is limited, and clinical efficient standardization requirements are difficult to meet. Extracting sample features and calling a parameter library according to rules to select optimal scanning and imaging parameters for initialization; starting an X / Y-axis motor according to the parameters, and correcting the deviation by combining an anti-interference rule and an encoder; z-axis dual-stage focusing is carried out after stable stopping, and an FPGA time sequence control camera carries out acquisition; aI judgment results are sent to images, suspicious cells are delineated and then positioned, and high-power lens re-focusing collection and AI recognition are carried out. The method has the advantages that sample adaptation and positioning precision is improved, suspicious cell recognition is optimized, and detection efficiency and precision are improved.

The invention relates to the technical field of small molecule polypeptides and leukemia treatment drugs, in particular to an EMBOW derived peptide targeting WDR5-MLL1 protein interaction and application of the EMBOW derived peptide, the amino acid sequence of the EMBOW derived peptide is shown as SEQ ID NO: 1, the N end of the EMBOW derived peptide is subjected to acetylation modification, and the C end of the EMBOW derived peptide is subjected to protective modification. The EMBOW derived peptide can target WDR5, inhibit protein interaction between WDR5-MLL1 and inhibit the methylation level of histone H3K4, and can be used for preparing a medicine for treating MLL1 gene rearrangement type leukemia.